BRPI0518894A2 - uso da cinase regulada por soro/glicocorticàide - Google Patents

uso da cinase regulada por soro/glicocorticàide

Info

Publication number
BRPI0518894A2
BRPI0518894A2 BRPI0518894-6A BRPI0518894A BRPI0518894A2 BR PI0518894 A2 BRPI0518894 A2 BR PI0518894A2 BR PI0518894 A BRPI0518894 A BR PI0518894A BR PI0518894 A2 BRPI0518894 A2 BR PI0518894A2
Authority
BR
Brazil
Prior art keywords
regulated kinase
glucocorticoid
serum
fragment
protein
Prior art date
Application number
BRPI0518894-6A
Other languages
English (en)
Inventor
Eckart Bartnik
Thomas Aigner
Uwe Dietz
Annette Brimmer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0518894A2 publication Critical patent/BRPI0518894A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DA CINASE REGULADA POR SOROIG LICOCORTICàIDE. A presente invenção refere-se ao uso de uma proteína de SGK, um derivado funcional ou fragmenta desta, ou um ácido nucléico que codifica uma tal proteína, fragmento ou derivado para descobrir ingredientes ativos para a prevenção ou tratamento de alterações degenerativas da cartilagem.
BRPI0518894-6A 2004-12-10 2005-12-01 uso da cinase regulada por soro/glicocorticàide BRPI0518894A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004059781A DE102004059781A1 (de) 2004-12-10 2004-12-10 Verwendung der Serum-/Glucocorticoid regulierten Kinase
PCT/EP2005/012802 WO2006061130A2 (de) 2004-12-10 2005-12-01 Verwendung der serum-/glucocorticoid regulierten kinase

Publications (1)

Publication Number Publication Date
BRPI0518894A2 true BRPI0518894A2 (pt) 2008-12-16

Family

ID=36571126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518894-6A BRPI0518894A2 (pt) 2004-12-10 2005-12-01 uso da cinase regulada por soro/glicocorticàide

Country Status (12)

Country Link
US (1) US20080274487A1 (pt)
EP (1) EP1825271B1 (pt)
JP (1) JP4971991B2 (pt)
KR (1) KR101362129B1 (pt)
CN (1) CN101073011A (pt)
AU (1) AU2005313576B2 (pt)
BR (1) BRPI0518894A2 (pt)
CA (1) CA2590212A1 (pt)
DE (1) DE102004059781A1 (pt)
IL (2) IL183466A (pt)
MX (1) MX2007006680A (pt)
WO (1) WO2006061130A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073675A1 (es) * 2008-09-26 2010-11-24 Sanofi Aventis Metodos para determinar la eficacia de los ligandos de los intercambiadores de sodio-proton
US20130072493A1 (en) 2011-09-19 2013-03-21 Sanofi N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
PT2570415E (pt) 2011-09-19 2015-11-23 Sanofi Sa N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas e a sua utilização como fármacos
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
WO2025072438A1 (en) 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
WO2001053455A2 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
ATE373676T1 (de) * 1998-12-14 2007-10-15 Univ Dundee Verfahren zur aktivierung von sgk durch phosphorylierung.
US6164979A (en) * 1999-03-12 2000-12-26 Motorola, Inc. System for providing a removable high density electrical interconnect for flexible circuits
WO2000073469A2 (en) * 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001055440A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030092611A9 (en) * 2000-01-31 2003-05-15 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2401541A1 (en) * 2000-03-06 2001-09-13 Sugen, Inc. Human protein kinases and protein kinase-like enzymes
US20030211989A1 (en) * 2001-03-02 2003-11-13 Plowman Gregory D Novel human protein kinases and protein kinase-like enzymes
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002223950A1 (en) * 2000-09-20 2002-04-02 Qlt Inc. Cancer associated protein kinases and their uses
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2004533840A (ja) * 2001-07-06 2004-11-11 ジェネンテック・インコーポレーテッド ファージディスプレイによるｐｄｚドメインリガンド
US6830911B2 (en) * 2002-02-08 2004-12-14 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
AU2003226444A1 (en) * 2002-04-01 2003-10-13 Asahi Kasei Pharma Corporation Vascularization controlling gene
AU2003229689A1 (en) * 2002-04-15 2003-10-27 Glaxo Group Limited A method of identifying a modudator for a serine/theronine kinase
US20040197792A1 (en) 2002-07-15 2004-10-07 Sugen, Inc. Novel Kinases
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
EP2322200A3 (en) * 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004042022A2 (en) * 2002-11-01 2004-05-21 Incyte Corporation Kinases and phosphatases
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2004065577A2 (en) * 2003-01-14 2004-08-05 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom

Also Published As

Publication number Publication date
AU2005313576B2 (en) 2011-11-17
IL212857A0 (en) 2011-07-31
WO2006061130A2 (de) 2006-06-15
WO2006061130A3 (de) 2007-04-26
MX2007006680A (es) 2007-08-14
EP1825271A2 (de) 2007-08-29
US20080274487A1 (en) 2008-11-06
EP1825271B1 (de) 2014-02-12
AU2005313576A1 (en) 2006-06-15
JP2008522596A (ja) 2008-07-03
CN101073011A (zh) 2007-11-14
IL183466A0 (en) 2007-09-20
KR101362129B1 (ko) 2014-02-14
DE102004059781A1 (de) 2006-06-22
JP4971991B2 (ja) 2012-07-11
IL183466A (en) 2013-08-29
CA2590212A1 (en) 2006-06-15
KR20070085965A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
CR11851A (es) Mutantes fgf21 y usos de los mismos
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
CO6362020A2 (es) Mutantes fgf21 y uso de los mismos
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
WO2006124863A3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
BRPI0611814A2 (pt) moduladores parp e tratamento de cÂnceres
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
BRPI0903359B8 (pt) composição farmacêutica de metformina, ácido acetilsalicílico e composto de serotonina para o tratamento do câncer
BRPI0609278B8 (pt) método para preparar uma composição farmacêutica e composição farmacêutica
BRPI0516533A (pt) método para o tratamento, inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero que dele necessita; produto; uso de um composto inibidor da tace; composição farmacêutica para o tratamento, a inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BRPI0519690A2 (pt) composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
BR112014001017A2 (pt) uso de um ou mais nucleotídeos para aperfeiçoar a estabilidade de calor de uma composição aquosa de caseína micelar; composição nutricional líquida; processo para o tratamento com calor de uma composição aquosa de caseína micelar; e método para prover nutrição a uma pessoa com necessidade desta
BR112023019999A2 (pt) Métodos para depletar seletivamente fragmentos não desejáveis de bibliotecas amplificadas de dna ou cdna mediante o uso de um ou mais oligonucleotídeos bloqueadores e kits para a preparação de biblioteca baseada em rna-seq

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.